NCT00092066View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)

PHASE3CompletedINTERVENTIONAL

Enrollment

717

Participants

Timeline

Start Date

September 24, 2003

Primary Completion Date

May 1, 2004

Study Completion Date

May 1, 2004

Conditions

OsteoporosisVitamin D Deficiency

Interventions

DRUG

MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks

All Listed Sponsors

lead

Organon and Co

INDUSTRY

NCT00092066 - A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) | Biotech Hunter | Biotech Hunter